Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903902864> ?p ?o ?g. }
- W2903902864 endingPage "527" @default.
- W2903902864 startingPage "516" @default.
- W2903902864 abstract "BACKGROUNDChronic lung allograft dysfunction (CLAD) is a major cause of post‒lung transplant mortality, with limited medical treatment options. In this study we assessed the association of montelukast treatment with pulmonary function and outcome in lung transplant recipients with progressive CLAD.METHODSWe performed a retrospective study of all lung transplant recipients transplanted between July 1991 and December 2016 at our center and who were treated for at least 3 months with montelukast for progressive CLAD, despite at least 3 months of prior azithromycin therapy. Main outcome parameters included evolution of pulmonary function and progression-free and overall survival.RESULTSA total of 153 patients with CLAD (115 with bronchiolitis obliterans syndrome and 38 with restrictive allograft syndrome) were included, of whom 46% had a forced expiratory volume in 1 second (FEV1) measure of between 66% and 80%, 31% an FEV1 between 51% and 65%, and 23% an FEV1 ≤50% of best post-operative FEV1 at start of montelukast. Montelukast was associated with attenuation in rate of FEV1 decline after 3 and 6 months, respectively (both p < 0.0001). Patients in whom FEV1 improved or stabilized after 3 months of montelukast (81%) had significantly better progression-free (p < 0.0001) and overall (p = 0.0002) survival after CLAD onset, as compared to those with further decline of FEV1 (hazard ratio [HR] 2.816, 95% confidence interval [CI] 1.450 to 5.467, p = 0.0022 for overall survival after CLAD onset in risk-adjusted multivariate analysis).CONCLUSIONSMontelukast was associated with a significant attenuation in rate of FEV1 decline in a substantial proportion of patients with established CLAD, which correlated with better outcome. Further study is required regarding use of montelkast. Chronic lung allograft dysfunction (CLAD) is a major cause of post‒lung transplant mortality, with limited medical treatment options. In this study we assessed the association of montelukast treatment with pulmonary function and outcome in lung transplant recipients with progressive CLAD. We performed a retrospective study of all lung transplant recipients transplanted between July 1991 and December 2016 at our center and who were treated for at least 3 months with montelukast for progressive CLAD, despite at least 3 months of prior azithromycin therapy. Main outcome parameters included evolution of pulmonary function and progression-free and overall survival. A total of 153 patients with CLAD (115 with bronchiolitis obliterans syndrome and 38 with restrictive allograft syndrome) were included, of whom 46% had a forced expiratory volume in 1 second (FEV1) measure of between 66% and 80%, 31% an FEV1 between 51% and 65%, and 23% an FEV1 ≤50% of best post-operative FEV1 at start of montelukast. Montelukast was associated with attenuation in rate of FEV1 decline after 3 and 6 months, respectively (both p < 0.0001). Patients in whom FEV1 improved or stabilized after 3 months of montelukast (81%) had significantly better progression-free (p < 0.0001) and overall (p = 0.0002) survival after CLAD onset, as compared to those with further decline of FEV1 (hazard ratio [HR] 2.816, 95% confidence interval [CI] 1.450 to 5.467, p = 0.0022 for overall survival after CLAD onset in risk-adjusted multivariate analysis). Montelukast was associated with a significant attenuation in rate of FEV1 decline in a substantial proportion of patients with established CLAD, which correlated with better outcome. Further study is required regarding use of montelkast." @default.
- W2903902864 created "2018-12-22" @default.
- W2903902864 creator A5004694001 @default.
- W2903902864 creator A5009982067 @default.
- W2903902864 creator A5030730695 @default.
- W2903902864 creator A5033618310 @default.
- W2903902864 creator A5034996987 @default.
- W2903902864 creator A5055245374 @default.
- W2903902864 creator A5055712465 @default.
- W2903902864 creator A5069256258 @default.
- W2903902864 creator A5071852923 @default.
- W2903902864 creator A5076531628 @default.
- W2903902864 creator A5082781557 @default.
- W2903902864 date "2019-05-01" @default.
- W2903902864 modified "2023-10-05" @default.
- W2903902864 title "Montelukast in chronic lung allograft dysfunction after lung transplantation" @default.
- W2903902864 cites W1540147815 @default.
- W2903902864 cites W1749324265 @default.
- W2903902864 cites W1884486122 @default.
- W2903902864 cites W1934676622 @default.
- W2903902864 cites W1936798053 @default.
- W2903902864 cites W1974783945 @default.
- W2903902864 cites W1983793588 @default.
- W2903902864 cites W2005593184 @default.
- W2903902864 cites W2013798647 @default.
- W2903902864 cites W2029708363 @default.
- W2903902864 cites W2032088650 @default.
- W2903902864 cites W2034383024 @default.
- W2903902864 cites W2060290334 @default.
- W2903902864 cites W2083435171 @default.
- W2903902864 cites W2104082131 @default.
- W2903902864 cites W2105795870 @default.
- W2903902864 cites W2105812451 @default.
- W2903902864 cites W2108592134 @default.
- W2903902864 cites W2115027948 @default.
- W2903902864 cites W2115591184 @default.
- W2903902864 cites W2119652843 @default.
- W2903902864 cites W2124369942 @default.
- W2903902864 cites W2139556962 @default.
- W2903902864 cites W2142926316 @default.
- W2903902864 cites W2147318351 @default.
- W2903902864 cites W2166559145 @default.
- W2903902864 cites W2167504776 @default.
- W2903902864 cites W2176787481 @default.
- W2903902864 cites W2255977664 @default.
- W2903902864 cites W2405514203 @default.
- W2903902864 cites W2407610499 @default.
- W2903902864 cites W2513186005 @default.
- W2903902864 cites W2550669699 @default.
- W2903902864 cites W2594107489 @default.
- W2903902864 cites W2618098759 @default.
- W2903902864 cites W2620225677 @default.
- W2903902864 cites W2796106000 @default.
- W2903902864 cites W2884626960 @default.
- W2903902864 doi "https://doi.org/10.1016/j.healun.2018.11.014" @default.
- W2903902864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30638839" @default.
- W2903902864 hasPublicationYear "2019" @default.
- W2903902864 type Work @default.
- W2903902864 sameAs 2903902864 @default.
- W2903902864 citedByCount "37" @default.
- W2903902864 countsByYear W29039028642018 @default.
- W2903902864 countsByYear W29039028642019 @default.
- W2903902864 countsByYear W29039028642020 @default.
- W2903902864 countsByYear W29039028642021 @default.
- W2903902864 countsByYear W29039028642022 @default.
- W2903902864 countsByYear W29039028642023 @default.
- W2903902864 crossrefType "journal-article" @default.
- W2903902864 hasAuthorship W2903902864A5004694001 @default.
- W2903902864 hasAuthorship W2903902864A5009982067 @default.
- W2903902864 hasAuthorship W2903902864A5030730695 @default.
- W2903902864 hasAuthorship W2903902864A5033618310 @default.
- W2903902864 hasAuthorship W2903902864A5034996987 @default.
- W2903902864 hasAuthorship W2903902864A5055245374 @default.
- W2903902864 hasAuthorship W2903902864A5055712465 @default.
- W2903902864 hasAuthorship W2903902864A5069256258 @default.
- W2903902864 hasAuthorship W2903902864A5071852923 @default.
- W2903902864 hasAuthorship W2903902864A5076531628 @default.
- W2903902864 hasAuthorship W2903902864A5082781557 @default.
- W2903902864 hasBestOaLocation W29039028642 @default.
- W2903902864 hasConcept C126322002 @default.
- W2903902864 hasConcept C141071460 @default.
- W2903902864 hasConcept C207103383 @default.
- W2903902864 hasConcept C2776042228 @default.
- W2903902864 hasConcept C2776322731 @default.
- W2903902864 hasConcept C2776739411 @default.
- W2903902864 hasConcept C2777714996 @default.
- W2903902864 hasConcept C2781448352 @default.
- W2903902864 hasConcept C44249647 @default.
- W2903902864 hasConcept C71924100 @default.
- W2903902864 hasConcept C75603125 @default.
- W2903902864 hasConcept C90924648 @default.
- W2903902864 hasConceptScore W2903902864C126322002 @default.
- W2903902864 hasConceptScore W2903902864C141071460 @default.
- W2903902864 hasConceptScore W2903902864C207103383 @default.
- W2903902864 hasConceptScore W2903902864C2776042228 @default.
- W2903902864 hasConceptScore W2903902864C2776322731 @default.
- W2903902864 hasConceptScore W2903902864C2776739411 @default.
- W2903902864 hasConceptScore W2903902864C2777714996 @default.